Comparison of the efficiency of anti-VEGF drugs intravitreal injections treatment with or without retinal laser photocoagulation for macular edema secondary to retinal vein occlusion: A systematic review and meta-analysis

Weijie Zou1†, Yuanyuan Du1†, Xiaoyan Ji1†, Ji Zhang1, Hongping Ding1, Jingqiao Chen1, Tao Wang2, Fangfang Ji1 and Jiang Huang1,3*

1Department of Ophthalmology, Second Affiliated Hospital of Soochow University, Suzhou, China, 2Department of Ophthalmology, Changshu No.1 People’s Hospital, Suzhou, China, 3State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China

Objective: To compare the efficiency of anti-VEGF drugs intravitreal injections(IVI) treatment with or without retinal laser photocoagulation(LPC) for macular edema(ME) secondary to retinal vein occlusion(RVO).

Methods: The randomized controlled trials and retrospective studies including anti-VEGF drug IVI combined with retinal LPC and single IVI in the treatment of macular edema secondary to RVO were collected in PubMed, Medline, Embase, Cochrane Library, and Web of Science. We extracted the main outcome indicators including the best corrected visual acuity (BCVA), central macular thickness(CMT), the number of injections and the progress of retinal non-perfusion areas(NPAs) for systematic evaluation, to observe whether IVI + LPC could be more effective on the prognosis of RVO. We use Review Manager 5.4 statistical software to analyze the data

Results: 527 articles were initially retrieved. We included 20 studies, with a total of 1387 patients who were divided into the combination(IVI + LPC) treatment group and the single IVI group. All the patients completed the ocular examination including BCVA, slit-lamp test, fundus examination and Optical Coherence Tomography(OCT) test before and after each treatment. There was no statistical difference between the combination treatment group and single IVI group on BCVA(WMD = 0.12,95%CI = -3.54–3.78,p = 0.95),CMT(WMD = -4.40,95%CI = -21.33–12.53,p = 0.61) and NPAs(WMD = 0.01,95%CI = -0.28–0.30,p = 0.94).However, the number of IVI was decreased significantly in the combination treatment group in BRVO patients,
compared to that in the single IVI group (WMD = -0.69, 95% CI = -1.18 to -0.21, p = 0.005).

Conclusion: In the treatment of RVO patients with macular edema, the combination of IVI and retinal LPC neither improves BCVA nor reduces CMT significantly compared with the single IVI treatment. However, the combination treatment can decrease the number of intravitreal injections in patients with BRVO, while it is not observed in CRVO patients.

KEYWORDS
anti-VEGF, laser photocoagulation, macular edema, retina vein occlusion, retinal non-perfused areas

Introduction
Retinal vein occlusion (RVO) is one of the most common retinal vascular diseases, with a global prevalence of 1–2% among people over 40 years old. According to the location of the occlusion, RVO can be divided into central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), and the prevalence of BRVO is 4 times that of CRVO (Rogers et al., 2010; Khayat et al., 2018). It is generally thought that RVO may be caused by mechanical damage and local inflammation of the vascular wall, which can result in thrombosis that blocks the main vein in the retinal circulation, and leads to increasing intravascular pressure, eventually causing hemorrhage and retinal edema (Jaulim et al., 2013; Noma et al., 2019). The common complications of RVO are macular edema, neovascularization, neovascular glaucoma, vitreous hemorrhage and so on (Jaulim et al., 2013; Schmidt-Erfurth et al., 2019). Macular edema plays the most important role in the irreversible vision loss of RVO patients. Therefore, treatments for macular edema of RVO are vital to prevent the decline of visual acuity and protect visual function. In the past, retinal LPC had always been the main treatment for RVO patients before anti-VEGF drugs were applied because of its convenience, good repeatability and low costs. However, limitations to LPC treatment are also prominent. For example, it cannot improve the visual acuity or regress the macular edema significantly.

In recent years, IVI of anti-VEGF drugs has been recommended as a first-line clinical treatment because of its excellent therapeutic effect on ME in RVO patients (Holz et al., 2013; Jaulim et al., 2013; Noma et al., 2019; Schmidt-Erfurth et al., 2019). It can improve the visual acuity and decrease ME significantly, while it needs repeated injections, with the increasing medical costs and potential risks (such as infection and cardiovascular accidents, etc.). In addition, some studies (Donati et al., 2012; Farese et al., 2014; Rehak et al., 2014; Tomomatsu et al., 2016; Goel et al., 2019; Terashima et al., 2019; An and Jeong, 2020; Nourinia et al., 2020) illustrated that retinal LPC combined with IVI treatment may be more effective and could reduce the number of injections and the medical costs. However, this conclusion is still controversial. The purpose of this study is to systematically analyze 20 related studies through meta-analysis, in order to evaluate the value of combination therapy for RVO patients with ME and to provide some valuable suggestions to choose a better treatment.

Materials and methods
This meta-analysis was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines.

Search strategy
Publications were searched on PubMed, Medline, Embase, Cochrane library and Web of science until February 2022. The detailed search terms were as follows:

1) "Retinal vein occlusion" [Mesh]/[Title/Abstract] OR "Central retinal vein occlusion" [Mesh]/[Title/Abstract] OR "CRVO" [Title/Abstract] OR "Branch retinal/vein occlusion" [Mesh]/[Title/Abstract] OR "BRVO" [Title/Abstract]
2) "Macular edema" [Mesh]/[Title/Abstract] OR "Macular oedema" [Mesh]/[Title/Abstract]
3) "Vascular Endothelium growth factor" [Mesh]/[Title/Abstract] OR "VEGF" [Title/Abstract] OR "anti-VEGF" [Title/Abstract] OR "bevacizumab" [Title/Abstract] OR "ranibizumab" [Title/Abstract] OR "lucentis" [Title/Abstract] OR "aflibercept" [Title/Abstract]
4) "Retinal laser photocoagulation" [Mesh]/[Title/Abstract] OR "Retinal photocoagulation" [Mesh]/[Title/Abstract]
5) Combine one and two and three and four

Inclusion and exclusion criteria
The following inclusion criteria were used for this study: (1) research subjects: clinically diagnosed patients with ME...
secondary to RVO; (2) interventions: intravitreal anti-VEGF drugs injections combined with laser photocoagulation (IVI + LPC) and single intravitreal anti-VEGF drugs injections (IVI); (3) research types: randomized controlled trials (RCTs) or retrospective studies; (4) result evaluation: best corrected visual acuity (BCVA), central macular thickness (CMT), the number of injections and retinal non-perfusion (NPAs); (5) the follow-up period of the study should be more than 6 months.

The followings are the exclusion criteria for this study: (1) case reports or review articles; (2) duplicate publication; (3) research lacking sufficient information; (4) recurrent patients with ME secondary to RVO; (5) patients with other ocular diseases, such as diabetic retinopathy, glaucoma, age-related macular degeneration, hyperopia and uveitis.

Data extraction and risk of bias assessment

The following information was collected from all the included studies: name of the first author, location, type of RVO, age, gender, intervention, BCVA, CMT, and follow-up periods. In our included studies, some authors used EDTRS letters while the others used LogMAR to represent BCVA. Therefore, we converted LogMAR into EDTRS letters (N) and make forest plots to illustrate the question for a better comparison. The conversion relationship is as follows:

\[ N = 100 - \frac{-0.3 + \log \text{MAR}}{-0.02} \]

We calculated the Jadad score to evaluate the risk of bias: 1–3 scores was considered low-quality research, 4–7 scores was considered medium-quality research and 8–11 scores was considered high-quality research.

The bias including selection bias, performance bias, detection bias, attrition bias, reporting bias, and other factors was examined.

Statistical analysis

The data analyses were performed by Review Manager 5.4 software, and the continuous variables are expressed by weighted mean difference (WMD) and 95% confidence interval (CI). The heterogeneity test was carried out by \( \chi^2 \) test to calculate the heterogeneous index (I\(^2\)). We used the fixed effect model for data analysis if no statistical heterogeneity was observed between the studies (\( p > 0.10, I^2 < 50% \)). On the contrary, if statistical heterogeneity was observed, the random effect model would be used. The statistical results of the amalgamation effect are expressed by the Z value, according to which we can get the corresponding p value. The metrological data (BCVA, CMT and NPAs) and counting data (injection numbers) are expressed as mean ± standard deviation (SD), and the results will be illustrated by forest plots.

Results

Search results

A total of 527 studies were identified by database search from January 2011 to February 2022. 196 duplicates articles were excluded, and a total of 331 articles were retrieved. After the titles and abstracts were carefully reviewed, 268 irrelevant studies were removed. In the remaining 63 studies, 43 studies were excluded mainly because of the lack of original data.
| Included studies | Location | Type of RVO | Interventions (Patients) | Age (years, $\bar{x} \pm s$) | Gender (M/F) | BCVA at baseline (letters, $\bar{x} \pm s$) | CMT at baseline ($\mu m$, $\bar{x} \pm s$) | Follow-up |
|------------------|----------|-------------|--------------------------|-----------------------------|-------------|-----------------------------------|-----------------------------------|-----------|
| Callizo et al. (2019) | Germany | BRVO | IVI + LPC (n = 16) | 67.30 ± 9.30 | 10/6 | 0.55 ± 0.26 logMAR | 496.10 ± 138.30 | 4,8,14,26,38 weeks |
| Cao et al. (2019) | China | BRVO | IVI + LPC (n = 20) | 66.80 ± 5.09 | 11/9 | 0.85 ± 0.35 logMAR | 456.10 ± 138.30 | 1,3,6,12 months |
| Chhablani et al. (2016) | India | CRVO | IVI + LPC (n = 11) | 45.90 ± 8.10 | NA | 3.20 ± 14.99 | 870.00 ± 295.00 | 6–12 months |
| Goel et al. (2019) | India | BRVO | IVI + LPC (n = 16) | 54.25 ± 9.56 | 6/10 | 0.88 ± 0.26 logMAR | 496.69 ± 964.03 | 1,3,6,9 months |
| Tomomatsu et al. (2016) | Japan | BRVO | IVI + LPC (n = 19) | 67.60 ± 8.32 | 9/10 | NA | NA | 1–6 months |
| Kumar et al. (2019) | India | BRVO | IVI + LPC (n = 15) | 57.93 ± 7.21 | 7/8 | 0.66 ± 0.14 logMAR | 491.47 ± 92.01 | 1,3,6 months |
| Tadayoni et al. (2016) | America | BRVO | IVI + LPC (n = 180) | 67.30 ± 10.41 | 96/84 | 56.60 ± 13.16 | 553.80 ± 170.06 | 1–6 months |
| Hayashi et al. (2011) | Japan | BRVO | IVI + LPC (n = 19) | 66.90 ± 12.00 | NA | 0.63 ± 0.40 logMAR | 537.00 ± 144.97 | 4,8,12,24 weeks |
| Donati et al. (2012) | Italy | BRVO | IVI + LPC (n = 9) | 54.99 ± 1.58 | NA | 0.66 ± 0.24 logMAR | 490.00 ± 149.10 | 1,2,3,6,12 months |
| Farese et al. (2014) | Italy | BRVO | IVI + LPC (n = 19) | 71.40 ± 8.00 | 11/8 | 0.50 ± 0.30 logMAR | 475.30 ± 96.10 | 1,3,6,12 months |
| Nourinia et al. (2020) | Iran | CRVO | IVI + LPC (n = 22) | 68.30 ± 11.00 | NA | 0.50 ± 0.25 logMAR | 568.40 ± 89.10 | 1–9 months |
| An and Jeong (2020) | Korea | BRVO | IVI + LPC (n = 17) | 59.00 ± 8.49 | 5/12 | 0.60 ± 0.49 logMAR | 677.00 ± 229.00 | 1–6 months |
| Terashima et al. (2019) | Japan | BRVO | IVI + LPC (n = 22) | 67.90 ± 8.90 | 10/12 | 0.60 ± 0.49 logMAR | 515.00 ± 172.00 | 1–6 months |

(Continued on following page)
20 studies were ultimately included in this meta-analysis study. The selection process is shown in Figure 1.

### Characteristics of included studies

A total of 1,387 patients with ME secondary to RVO were included in 20 studies including 16 randomized controlled trials and 4 retrospective studies. The general data of all patients were shown in Table 1. There was no significant difference in age (t = -0.0954, p = 0.924) and sex (χ² = 1.19, p > 0.05) between the IVI + LPC group and the single IVI group (Table 1).

### Risk of bias assessment

Methodological quality and bias risk assessment showed that there was no high risk of bias in our included studies, while the unclear risk of bias was mainly focused on the allocation concealment and the blinding of outcome assessment. In a word, selection bias and detection bias were the most common biases in this study (Figure 2).

### Results of meta-analysis

BCVA was reported in 16 studies with a total of 1205 RVO patients before and after treatment, including 941 BRVO patients and 264 CRVO patients (Hayashi et al., 2011; Donati et al., 2012; Farese et al., 2014; Rehak et al., 2014; Pielen et al., 2015; Clark et al., 2016; Tadayoni et al., 2016; Tultseva et al., 2017; Callizo et al., 2019; Cao et al., 2019; Goel et al., 2019; Kumar et al., 2019; Terashima et al., 2019; An and Jeong, 2020; Nourinia et al., 2020; Song et al., 2020). The results of random effect model analysis (p < 0.00001, I² = 86%) showed that IVI is not inferior to IVI + LPC (WMD = 0.12, 95% CI = -3.54–3.78, p = 0.95), neither in

| Included studies | Location | Type of RVO | Interventions (Patients) | Age(years, x ± s) | Gender(M/F) | BCVA at baseline (letters, x ± s) | CMT at baseline (µm, x ± s) | Follow-up |
|------------------|----------|-------------|--------------------------|------------------|-------------|----------------------------------|----------------------------|-----------|
| Song et al. (2020) | China | BRVO | IVI + LPC(n = 34) | 58.40 ± 9.70 | 18/16 | 54.40 ± 9.80 | 571.60 ± 223.50 | 1–12 months |
| | | | IVI(n = 30) | 59.60 ± 11.00 | 17/13 | 59.30 ± 8.30 | 516.10 ± 161.0 | |
| Rehak et al. (2014) | Germany | CRVO | IVI + LPC(n = 10) | 63.70 ± 19.20 | 5/5 | 61.60 ± 12.70 | 452.60 ± 266.80 | 1–6 months |
| | | | IVI(n = 12) | 63.70 ± 10.10 | 5/7 | 58.60 ± 12.50 | 466.70 ± 308.90 | |
| Pielen et al. (2015) | Germany | BRVO | IVI + LPC(n = 10) | 65.90 ± 11.20 | 6/4 | 0.41 ± 0.11 logMAR | 505.70 ± 81.80 | 1,4,12,24 weeks |
| | | | IVI(n = 10) | 64.20 ± 8.60 | 4/6 | 0.53 ± 0.24 logMAR | 584.20 ± 250.90 | |
| Clark et al. (2016) | America | BRVO | IVI + LPC(n = 90) | 63.90 ± 11.40 | 54/36 | 57.70 ± 11.30 | 553.50 ± 188.10 | 1,6,12 months |
| | | | IVI(n = 91) | 67.00 ± 10.40 | 44/47 | 58.60 ± 11.40 | 559.90 ± 185.90 | |
| Thomley et al. (2021) | America | BRVO | IVI + LPC(n = 32) | 73.50 ± 9.60 | NA | NA | 501.32 ± 223.04 | 1–36 months |
| | | | IVI(n = 56) | 71.50 ± 10.00 | NA | NA | 484.12,140.73 | |
| Ou et al. (2018) | America | RVO | IVI + LPC(n = 24) | 64.10 ± 10.68 | 13/11 | 51.70 ± 20.20 | 525.50 ± 250.40 | 1,4,9,12 months |
| | | | IVI(n = 6) | 63.80 ± 11.59 | 2/4 | 55.30 ± 21.70 | 471.50 ± 243.60 | |
| Tultseva et al. (2017) | Russia | CRVO | IVI + LPC(n = 88) | 62.50 ± 12.90 | 36/52 | 0.25 ± 0.15 logMAR | 410.20 ± 157.25 | 1–28 months |
| | | | IVI(n = 87) | 61.70 ± 11.40 | 34/53 | 0.27 ± 0.09 logMAR | 425.50 ± 210.14 | |

BRVO, branch retinal vein occlusion. CRVO, central retinal vein occlusion. IVI, intravitreal injection. LPC, laser photocoagulation. BCVA, best corrected visual acuity. CMT, central macular thickness. NA, not available. Data are presented as mean ± standard deviation where applicable.
BRVO patients (WMD = -2.01, 95% CI = -4.37 – 0.34, p = 0.09), nor in CRVO patients (WMD = 5.82, 95% CI = -3.65 – 15.29, p = 0.23) (Figure 3).

The CMT was described in 17 studies with 1101 RVO patients including 989 BRVO patients and 287 CRVO patients (Hayashi et al., 2011; Donati et al., 2012; Farese et al., 2014; Rehak et al., 2014; Tomomatsu et al., 2016; Tultseva et al., 2017; Callizo et al., 2019; Goel et al., 2019; Kumar et al., 2019; Terashima et al., 2019; Nourinia et al., 2020; Song et al., 2020; Thomley et al., 2021). The fixed effect model analysis (p = 0.27, I² = 16%) demonstrated that there was no significant difference in CMT between IVI + LPC group and IVI group (WMD = -4.40, 95% CI = -21.33 – 12.53, p = 0.61), whether in BRVO patients (WMD = -1.84, 95% CI = -19.98 – 16.30, p = 0.84) or in CRVO patients (WMD = -21.72, 95% CI = -68.89 – 25.45, p = 0.37) (Figure 4).

The number of injections was recorded in 11 studies with 419 RVO patients including 329 BRVO patients and 265 CRVO patients (Donati et al., 2012; Farese et al., 2014; Chhablani et al., 2016; Tomomatsu et al., 2016; Tultseva et al., 2017; Callizo et al., 2019; Goel et al., 2019; Terashima et al., 2019; An and Jeong, 2020; Nourinia et al., 2020; Thomley et al., 2021). The results of the random effect model analysis (p < 0.00001, I² = 97%) illustrated that there was no significant difference between the IVI + LPC group and the single IVI group (WMD = -1.14, 95% CI = -2.51 – 0.23, p = 0.10) (Figure 5).

Further subgroup analysis demonstrated that in BRVO patients with ME, the number of injections was sharply decreased in the combination treatment group compared with the single IVT treatment group (WMD = -0.69, 95% CI = -1.18 – 0.21, p = 0.005). However, there was no significant difference in the number of injections between the combined treatment group and the single IVI group in CRVO patients with ME (WMD = -1.72, 95% CI = -6.04 – 2.60, p = 0.44) (Figure 5).

The progress of NPAs was recorded and quantified by three studies with 74 RVO patients (Rehak et al., 2014; Ou et al., 2018; Callizo et al., 2019). The results of the fixed effect model analysis (p = 0.15, I² = 47%) showed that no significant differences were detected in the change of NPAs areas between the combined treatment group and the single IVI group (WMD = 0.01, 95% CI = -0.28 – 0.30, p = 0.94) (Figure 6).

**Discussion**

At present, the main treatments for RVO patients with ME include intravitreal injection of anti-VEGF or corticosteroid drugs, retinal laser photoagulation and surgeries. The IVI of anti-VEGF drug therapy has been recommended as the first-line clinical medication, because of its outstanding effect in improving the visual acuity and reducing ME. However, the medical risks (such as infection and cardiovascular accidents) and the economic burden should not be ignored, as it needs repeated injections. Therefore, how to decline the number of IVI treatment in RVO patients is one of the current research hotspots. Recently, some studies (Donati et al., 2012; Farese et al., 2014; Rehak et al., 2014; Tomomatsu et al., 2016; Tultseva et al., 2017; Goel et al., 2019; Terashima et al., 2019; An and Jeong, 2020; Nourinia et al., 2020) have found that, compared with single IVI, the combination of IVI and LPC could improve the prognosis in RVO patients with ME and decrease the number of injections. However, other studies (Hayashi et al.,...
2011; Pielen et al., 2015; Chhablani et al., 2016; Tadayoni et al., 2016; Callizo et al., 2019; Cao et al., 2019; Kumar et al., 2019; Song et al., 2020; Thomley et al., 2021) suggested that combination treatment could neither improve the prognosis of patients nor reduce the frequency of IVI, and on the contrary, it has increased the medical burden of RVO patients.

The results of this study demonstrated that both the combined treatment and single IVI treatment can effectively improve BCVA and decrease CMT in RVO patients with ME. However, no obvious evidence showed that additional laser photocoagulation could further amplify the benefits of IVI on BCVA and CMT. In addition, the combined treatment can reduce the number of injections conspicuously in BRVO patients with ME, however, the difference was not found in CRVO patients. The results suggested that additional laser photocoagulation cannot delay the progress of NPAs in CRVO patients with ME, while it may be helpful to the progress of NPAs in BRVO patients.

A possible mechanism is that combined (IVI + LPC) treatment may slow down the progress of retinal non-perfused areas (NPAs) in BRVO patients. Previous studies (Stefánsson, 2001; Tomomatsu et al., 2016) have proved that hypoxia plays an important role in the pathogenesis of RVO with ME. Hypoxia increases the expression of VEGF and vascular permeability, which leads to vascular leakage and macular edema. Anti-VEGF drugs can effectively inhibit this process and decline the severity of ME by reducing the damage to the blood-retinal barrier. However, because of the short half-life of anti-VEGF drugs, the intraocular drug concentration decreases rapidly, and the peripheral retinal NPAs continue to release VEGF, resulting in the recurrence of ME. Some studies (Rehak et al., 2014; Tan et al., 2016) have shown that the size of NPAs is related to the severity of BRVO, and after being combined with LPC, it partially destroyed the peripheral retinal pigment epithelia and photoreceptors, declined the tissue hypoxia and inhibit the release of VEGF from retinal NPAs. And eventually, it slowed down the progress of NPAS.

Some studies (Kokolaki et al., 2015; An and Jeong, 2020) also suggested that early LPC treatment could promote the formation of collateral vessels in retinal NPAs in BRVO patients. With the extension of time after laser photocoagulation, the number of collateral vessels parallelly increases at the same time. Finally, the time of collateral vessels formation in patients with combined therapy (IVI + LPC) is less than that in patients with anti-VEGF drugs alone (Rehak et al., 2014). By declining NPAs, additional LPC could improve the function of the collateral vessels and FIGURE 3

Comparison of BCVA between combination (IVI + LPC) treatment group and single IVI treatment group.
### FIGURE 4
Comparison of CMT between combination (IVI + LPC) treatment group and single IVI treatment group.

| Study or Subgroup | IVI-LPC | IVI | Mean Difference Mean Difference |
|-------------------|---------|----|---------------------------------|
|                   | Mean    | SD | Total Mean | SD | Total | Weight | IV, Fixed | 95% CI | IV, Fixed | 95% CI |
| 1.2.2 CRVO        |         |    |            |    |       |         |           |        |           |        |
| Chhablani J 2016  | -228.0  | 266.69 | 11 | -314     | 289.77 | 12 | 0.6% | 86.00 | [141.41, 313.41] |
| Elvira Farase 2014| -194.3  | 140.16 | 10 | -109.6   | 115.8  | 9 | 2.2% | -94.07 | [-199.90, 30.50] |
| Matus Rehak 2013  | -178.5  | 301.2  | 10 | -159.9   | 336.7  | 12 | 0.4% | -18.80 | [-285.32, 248.12] |
| Ramin Nourinia 2014| -455.2 | 249.98 | 24 | -391.36  | 251.84 | 24 | 1.4% | -84.06 | [-206.02, 77.90] |
| Svetlana N. Tutsheva 2017 | -253.5 | 211.12 | 88 | -248.173 | 183.73 | 87 | 8.3% | -5.50 | [-64.12, 53.12] |
| Subtotal (95% CI) | 143.0    | 12.9% | 144 | -21.72 | [68.88, 25.45] |
| Heterogeneity: | Chi² = 2.65, df = 4 (P = 0.62); I² = 0% |
| Test for overall effect: Z = 0.90 (P = 0.37) |
| Total (95% CI) | 623.0 | 100.0 | 653 | -4.40 | [-21.33, 12.53] |
| Heterogeneity: | Chi² = 20.15, df = 17 (P = 0.02); I² = 16% |
| Test for overall effect: Z = 0.51 (P = 0.61) |
| Test for subgroups: Chi² = 0.59, df = 1 (P = 0.44); I² = 0% |

FIGURE 5
Comparison of the number of injections between combination (IVI + LPC) treatment group and single IVI treatment group.

| Study or Subgroup | IVI-LPC | IVI | Mean Difference Mean Difference |
|-------------------|---------|----|---------------------------------|
|                   | Mean    | SD | Total Mean | SD | Total | Weight | IV, Random | 95% CI | IV, Random | 95% CI |
| 1.3.1 BRVO        |         |    |            |    |       |         |           |        |           |        |
| Elvira Farase 2014| 2.74    | 1.69 | 19 | 3.125   | 1.92  | 16 | 8.4% | -0.38 | [-1.56, 0.79] |
| Hiroko Terashima 2018 | 1.9 | 0.8 | 22 | 2.3 | 0.9 | 24 | 8.9% | -0.40 | [-1.89, 0.09] |
| Josep Calillo 2019 | 3.94 | 0.85 | 16 | 3.63 | 0.62 | 16 | 8.9% | 0.31 | [-0.21, 0.83] |
| Meredith E. Thornley 2021 | 5.89 | 5.2 | 32 | 7 | 3.71 | 56 | 7.5% | -1.11 | [-3.16, 0.94] |
| Seoung Hyun An 2019 | 2.14 | 2.26 | 17 | 3.57 | 2.33 | 23 | 7.9% | -1.43 | [-3.13, 0.27] |
| Siddhi Goel 2020 | 4.06 | 0.99 | 16 | 5.76 | 1.37 | 13 | 17.8% | -1.70 | [-2.49, -0.91] |
| Simone Donati 2012 | 3.0 | 0.49 | 16 | 4 | 1 | 11 | 9.7% | -1.00 | [-1.76, -0.24] |
| Yoko Tomomatsu 2016 | 0.83 | 0.62 | 18 | 1.58 | 0.69 | 19 | 8.9% | -0.75 | [-1.17, -0.33] |
| Subtotal (95% CI) | 149.0 | 67.8% | 180 | -6.69 | [-1.18, -0.21] |
| Heterogeneity: | Tau² = 0.29; Chi² = 22.85, df = 7 (P = 0.002); I² = 69% |
| Test for overall effect: Z = 2.81 (P = 0.005) |
| 1.3.2 CRVO        |         |    |            |    |       |         |           |        |           |        |
| Chhablani J 2016  | 6.7     | 3.59 | 11 | 6 | 3.17 | 12 | 6.6% | 0.70 | [-2.08, 3.48] |
| Elvira Farase 2014 | 3.5    | 2.01 | 10 | 1.89 | 1.05 | 9 | 8.2% | 1.61 | [0.19, 3.03] |
| Ramin Nourinia 2019 | 4.05 | 1.09 | 24 | 5.83 | 1.95 | 24 | 8.6% | -1.78 | [-2.67, -0.89] |
| Svetlana N. Tutsheva 2017 | 3.5 | 1.6 | 88 | 10.6 | 2.5 | 87 | 8.8% | -7.10 | [-7.72, -6.48] |
| Subtotal (95% CI) | 133.0 | 32.2% | 132 | -1.72 | [-0.64, 2.60] |
| Heterogeneity: | Tau² = 18.75; Chi² = 166.79, df = 3 (P < 0.00001); I² = 98% |
| Test for overall effect: Z = 0.78 (P = 0.44) |
| Total (95% CI) | 282.0 | 100.0% | 312 | -1.14 | [-2.51, 0.23] |
| Heterogeneity: | Tau² = 5.46; Chi² = 413.31, df = 11 (P < 0.00001); I² = 97% |
| Test for overall effect: Z = 1.63 (P = 0.10) |
| Test for subgroups: Chi² = 0.21, df = 1 (P = 0.64); I² = 0% |
inhibit the release of VEGF. Then, it ameliorates the state of hypoxia and oxidative stress in the whole retina and delays the recurrence of macular edema.

On the other hand, for patients with CRVO, it is not clear why combined treatment cannot improve the prognosis or reduce the number of IVI. The possible reasons are as follows: (1) As it is known that, CRVO can be divided into ischemic CRVO and nonischemic CRVO, ischemic CRVO has a risk of neovascularization (NV) while there is no risk of NV associated with nonischemic CRVO. Some researchers thought that laser photocoagulation could play an important role in the treatment of NV, thus improving the prognosis of ischemic CRVO patients. However, for nonischemic CRVO patients, LPC could have no treatment effect (Hayreh, 2021). We could not conduct a more detailed analysis because of the limitation of the data we extracted in our included studies. Therefore, our results may be influenced by the absence of hierarchical analysis of CRVO. (2) Compared to the relatively limited pathological changes in BRVO, the larger retinal areas were affected by CRVO, which may diminish the efficiency of additional LPC. (3) Although pan-retinal photocoagulation (PRP) for CRVO patients could reduce the level of intraocular VEGF, it also causes the incline of intraocular inflammatory factors, which is not beneficial for the regression of macular edema. (4) Pan-retinal photocoagulation can close the capillary NPAs, however, it still leads to a wide range of non-vascularized areas around NPAs in CRVO. And the perfusion of the whole retina cannot match the demand for blood oxygen of the retina, as the intraocular VEGF is continuously released. Thus the combination of IVI and retinal LPC cannot delay the recurrence of CRVO with macular edema.

To our knowledge, this meta-analysis is the first study that concludes all the available research data in the recent 10 years of intravitreal injection of anti-VEGF drugs and retinal laser photocoagulation in RVO patients with ME. However, the limitations of this study are as follows: (1) The published clinical research data is still not sufficient because of the lack of indicators for the treatment of RVO in some anti-VEGF drugs. (2) Because the related studies involving different types of anti-VEGF drugs, varies greatly, the heterogeneity and publication bias of statistical analysis cannot be avoided. (3) Considering the limitation of the data we extracted in our included studies, some detailed analysis cannot be conducted between subgroups, which may influence our final results. Therefore, it is necessary to include more studies for further analysis in the future.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author Contributions

JH designed the study, drafted and revised the manuscript. WZ, YD, and XJ conducted the literature searches, data collection, wrote the statistical analysis plan and drafted the manuscript. JZ, HD, JC, TW, and FJ analysed the data.

Funding

This work was supported by Jiangsu Traditional Chinese Medicine Science and Technology Development Program Project (YB2020060) the Project of State Key Laboratory of Radiation Medicine and Protection, Soochow University (No. GZK1202141); the Second affiliated hospital of Soochow University Research fund project (SDFEYBS 1903) the Clinical Research Center of Neurological Disease fund project of the Second Affiliated Hospital of Soochow University (ND 2022B06).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Laser photocoagulation for macular edema secondary to branch retinal vein occlusion.

Comparison of the safety and efficacy of ranibizumab alone versus ranibizumab with or without grid laser photocoagulation for macular edema secondary to central retinal vein occlusion. A randomized double-masked controlled clinical trial. Retina 40 (6), 1110–1117. doi:10.1097/IAE.0b013e3182502f73

Nourinia, R., Emamverdi, M., Ramezani, A., Amizadeh, Y., Khoshdelifar, M., Behnazi, N., et al. (2020). Peripheral ischemic retinal photocoagulation in addition to intravitreal bevacizumab versus intravitreal bevacizumab alone for the treatment of macular edema secondary to central retinal vein occlusion: A randomized double-masked controlled clinical trial. Retinal Vascular 40 (4), 258–264. doi:10.1097/RIV.00000000000002573

Ou, W. C., Lampen, S. I. R., and Wykoff, C. C. (2018). Longitudinal quantification of retinal non-perfusion in the macula of eyes with retinal vein occlusion receiving anti-VEGF therapy: Secondary analysis of the WAVE randomized trial. Ophthalmic Surg. Lasers Imaging Retina 49 (4), 258–264. doi:10.3928/23258160-201810329-08

Pielen, A., Mirshahi, A., Fellgen, N., Lorenz, K., Korb, C., Junker, B., et al. (2015). Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): Six-month results of a prospective randomised controlled trial. Acta Ophthalmol. 93 (1), e29–37. doi:10.1111/aos.12488

Rehak, M., Tülgner, E., Franke, A., Rauscher, F. G., Brosteaua, O., Wiedemann, P., et al. (2014). Early peripheral laser photocoagulation of non-perfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study). Graefes Arch. Clin. Exp. Ophthalmol. 252 (5), 745–752. doi:10.1007/s00417-013-2528-8

Rogers, S., McIntosh, R. L., Cheung, N., Lim, L., Wang, J. J., Mitchell, P., et al. (2010). The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117 (2), 313–319. e311. doi:10.1016/j.ophtha.2009.07.017

Stefanoff, E. (2001). The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol. Scand. 79 (5), 435–440. doi:10.1034/j.1600-0420.2001.790502

Tadayoni, R., Waldstein, S. M., Bocca, F., Gerdling, H., Pearce, F., Frühlinger, S., et al. (2016). Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: Six-month results of BRIGHTER. Ophthalmology 123 (6), 1332–1344. doi:10.1016/j.ophtha.2016.02.030

Tan, C. S., Chew, M. C., Lim, L. W., and Sadda, S. R. (2016). Advances in retinal imaging for diabetic retinopathy and diabetic macular edema. Indian J. Ophthalmol. 64 (1), 76–83. doi:10.4103/0301-4738.178145

Terasihama, H., Hasebe, H., Okamoto, F., Matsuoka, N., Sato, Y., Fukuuchi, S., et al. (2019). Combination therapy of intravitreal ranibizumab and subthreshold micropulse photocoagulation for macular edema secondary to branch retinal vein occlusion: 6-MONTH result. Retina 39 (7), 1377–1384. doi:10.1097/IAE.0000000000002165

Tomley, M. E., Gross, C. N., Preda-Natmessuc, A., Chen, K. S., Swain, T., Mason, J. O., Ii, et al. (2021). Real-world outcomes in patients with branch retinal vein occlusion (BRVO)-related macular edema treated with anti-VEGF injections alone versus anti-VEGF injections combined with focal laser. J. Ophthalmology 2021, 752. doi:10.1155/2021/752839

Tulsitova, S. N., Astakhov, Y. S., Novikov, S. A., Nechiporenko, P. A., Lisochkina, A. B., Ovananyan, A. Y., et al. (2017). Alternative ways to optimize treatment for retinal vein occlusion with peripheral capillary non-perfusion: A pilot study. Acta Ophthalmol. 80 (4), 224–228. doi:10.1111/aos.12721